Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

1.4K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.4K
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

357
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
357
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

415
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
415
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

486
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
486
Drug Binding to Blood Components01:30

Drug Binding to Blood Components

381
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
381
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

455
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
455

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utilization and effectiveness of nutrition resources in primary healthcare settings: a systematic search and review.

The International journal of pharmacy practice·2025
Same author

Fecal Microbiome in Women With Fibromyalgia: Functional Composition and Symptom Correlations.

ACR open rheumatology·2025
Same author

Characterisation of the Oral Microbiome in Women With Fibromyalgia: An Observational Case-Control Study.

European journal of pain (London, England)·2025
Same author

N-Acetylcysteine Attenuates Aβ-Mediated Oxidative Stress, Blood-Brain Barrier Leakage, and Renal Dysfunction in 5xFAD Mice.

International journal of molecular sciences·2025
Same author

Fluorescence-Guided Resection of GL261 Red-FLuc and TRP-mCherry-FLuc Mouse Glioblastoma Tumors.

Cancers·2025
Same author

Plasma S100β is a predictor for pathology and cognitive decline in Alzheimer's disease.

Fluids and barriers of the CNS·2025

Related Experiment Video

Updated: Dec 6, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.6K

Mamma Mia, P-glycoprotein binds again.

Richard Callaghan1, Ingrid C Gelissen2, Anthony M George3

  • 1Research School of Biology, and the Medical School, Australian National University, Canberra, ACT, Australia.

FEBS Letters
|October 6, 2020
PubMed
Summary
This summary is machine-generated.

This study proposes that P-glycoprotein, a known transporter, may facilitate amyloid peptide exit from neurons. This mechanism could be crucial for regulating brain amyloid levels and preventing neurodegenerative diseases.

Keywords:
ABCB1Alzheimer’s diseaseMDR1Pgpamyloid peptidesblood-brain barrierhydrophobic peptidesmembrane transport

More Related Videos

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling
11:08

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling

Published on: February 5, 2018

9.0K
Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis
08:09

Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis

Published on: January 7, 2017

11.0K

Related Experiment Videos

Last Updated: Dec 6, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.6K
Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling
11:08

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling

Published on: February 5, 2018

9.0K
Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis
08:09

Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis

Published on: January 7, 2017

11.0K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Brain amyloid peptide levels are regulated by neuronal clearance pathways.
  • Amyloid peptides are hydrophobic and interact with cell membranes.
  • P-glycoprotein aids amyloid clearance across the blood-brain barrier, but its neuronal role is unclear.

Purpose of the Study:

  • To investigate the potential role of P-glycoprotein in mediating amyloid peptide 'exit' from neurons.
  • To explore the plausibility of P-glycoprotein transporting amyloid peptides based on their properties.

Main Methods:

  • Review of existing biochemical and structural models of P-glycoprotein.
  • Analysis of physicochemical similarities between amyloid peptides and known P-glycoprotein substrates.
  • Examination of potential transport mechanisms considering peptide size.

Main Results:

  • Amyloid peptides share properties with P-glycoprotein substrates.
  • The larger size of amyloid peptides presents a challenge for P-glycoprotein transport.
  • Evolving models suggest potential mechanisms for P-glycoprotein-mediated amyloid transport.

Conclusions:

  • P-glycoprotein is a plausible mediator of amyloid peptide efflux from neurons.
  • Understanding this mechanism is key to developing strategies for brain amyloid clearance.
  • Further research is needed to elucidate the precise transport mechanism.